SUPPLEMENT

Q4 2022 — Earnings infographic

Q4 2022PDF · 1 pages4.2 MB
Joaquin Duato
Chairman of the Board &
Chief Executive Officer
Johnson & Johnson
“Our full year 2022 results reflect the continued
strength and stability of our three business
segments, despite macroeconomic challenges.
I am inspired by our employees who make a
difference in the health and lives of people around
the world every day. As we look ahead to 2023,
Johnson & Johnson is well-positioned to drive
near-term growth, while also investing strategically
to deliver long-term value.”
For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on January 24, 2023 available at
http://www.investor.jnj.com/sales-earnings.cfm.
*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
Non-GAAP measure; excludes the impact of translational currency.
Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on
operational changes.
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation
Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are
based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially
from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-
Looking Statements” included in the Johnson & Johnson earnings release issued on January 24, 2023 as well as the most recently filed Johnson & Johnson
Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
Increased Decreased 	
Full Year 2022 Results
2022 Sales
Adjusted Diluted Earnings Per Share*
$10.15 	3.6%
Diluted Earnings Per Share
$6.73 	(13.8)%
Worldwide
Increased 
$94.9B 	6.2%*
1.3%
Worldwide
Increased  	Excluding acquisitions/
divestitures on an
operational basis
Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.
$27.4MedTech worldwide reported sales increased 1.4% or 6.2%
operationally. Primary operational drivers:
 
Worldwide MedTech Sales
Billion
Billion
$52.6 Worldwide Pharmaceutical Sales²Pharmaceutical worldwide reported sales increased 1.7%
or 6.7% operationally. Primary operational drivers:
Consumer Health worldwide reported sales decreased (0.5)%,
but increased 3.6% operationally. Primary operational drivers:
$15.0 	Worldwide Consumer Health Sales²
Billion
Wound Closure	Electrophysiology 	Contact Lens
Hips
Trauma
Endocutters	Biosurgery	Knees 	Energy
Surgical Vision

-- 1 of 1 --